Post-infarct remodelling: Contribution of wound healing and inflammation

Cardiovascular Research

Volumn 81, Issue 3, 2009, Pages 474-481

  Frantz, Stefan ^a   Bauersachs, Johann ^a   Ertl, Georg ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Healing; Inflammation; Myocardial infarction

Indexed keywords

ALPHA CHEMOKINE; ANTIINFLAMMATORY AGENT; BLOOD CLOTTING FACTOR 13; CD11 ANTIGEN; CD18 ANTIGEN; CHEMOKINE; COMPLEMENT; COMPLEMENT INHIBITOR; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 8; MINERALOCORTICOID ANTAGONIST; MONOCLONAL ANTIBODY; PEXELIZUMAB; RANTES; STEROID; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 6; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; UNINDEXED DRUG;

ACUTE HEART INFARCTION; ANTIINFLAMMATORY ACTIVITY; BLOOD CLOTTING; CELLULAR IMMUNITY; CLINICAL TRIAL; COMPLEMENT SYSTEM; CYTOKINE RELEASE; FIBRINOLYSIS; HEART FAILURE; HEART INFARCTION; HEART INFARCTION SIZE; HEART INJURY; HEART VENTRICLE REMODELING; HUMAN; HUMORAL IMMUNITY; IMMUNOMODULATION; INFLAMMATION; MACROPHAGE; MEDIATOR RELEASE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; WOUND HEALING;

ANIMALS; ANTIBODY FORMATION; HUMANS; IMMUNITY, CELLULAR; INFLAMMATION; INFLAMMATION MEDIATORS; MYOCARDIAL INFARCTION; MYOCARDIUM; PROGNOSIS; VENTRICULAR REMODELING; WOUND HEALING;

EID: 59449085857     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn292     Document Type: Review

References (86)

1. McKay RG, Pfeffer MA, Pasternak RC, Markis JE, Come PC, Nakao S et al. Left ventricular remodeling after myocardial infarction: a corollary to infarct expansion. Circulation 1986;74:693-702.
2. Ertl G, Frantz S. Healing after myocardial infarction. Cardiovasc Res 2005;66:22-32.
3. Frantz S, Bauersachs J, Kelly RA. Innate immunity and the heart. Curr Pharm Des 2005;11:1279-1290.
4. Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 1989;54(Pt 1):1-13.
5. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124:783-801.
6. Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999;5:1249-1255.
7. Frantz S, Ertl G, Bauersachs J. Mechanisms of disease: toll-like receptors in cardiovascular disease. Nat Clin Pract 2007;4:444- 454.
8. Frantz S, Ertl G, Bauersachs J. Toll-like receptor signaling in the ischemic heart. Front Biosci 2008;13:5772-5779.
9. Frantz S, Kelly RA, Bourcier T. Role of TLR-2 in the activation of nuclear factor-kappa B by oxidative stress in cardiac myocytes. J Biol Chem 2001;276:5197-5203.
10. Frantz S, Kobzik L, Kim YD, Fukazawa R, Medzhitov R, Lee RT et al. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest 1999;104:271-280.
11. Birks EJ, Felkin LE, Banner NR, Khaghani A, Barton PJ, Yacoub MH. Increased toll-like receptor 4 in the myocardium of patients requiring left ventricular assist devices. J Heart Lung Transplant 2004;23:228- 235.
12. Shishido T, Nozaki N, Yamaguchi S, Shibata Y, Nitobe J, Miyamoto T et al. Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation 2003;108:2905-2910.
13. Riad A, Jager S, Sobirey M, Escher F, Yaulema-Riss A, Westermann D et al. Toll-like receptor-4 modulates survival by induction of left ventricular remodeling after myocardial infarction in mice. J Immunol 2008;180:6954-6961.
14. Oyama J, Blais C Jr, Liu X, Pu M, Kobzik L, Kelly RA et al. Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation 2004;109:784-789.
15. Hall G, Hasday JD, Rogers TB. Regulating the regulator: NF-kappaB signaling in heart. J Mol Cell Cardiol 2006;41:580-591.
16. Morgan EN, Boyle EM Jr, Yun W, Griscavage-Ennis JM, Farr AL, Canty TG Jr et al. An essential role for NF-kappaB in the cardioadaptive response to ischemia. Ann Thorac Surg 1999;68:377-382.
17. Chandrasekar B, Freeman GL. Induction of nuclear factor kappaB and activation protein 1 in postischemic myocardium. FEBS Lett 1997;401:30-34.
18. Morishita R, Sugimoto T, Aoki M, Kida I, Tomita N, Moriguchi A et al. In vivo transfection of cis element 'decoy' against nuclear factor-kappaB binding site prevents myocardial infarction. Nat Med 1997;3:894-899.
19. Brown M, McGuinness M, Wright T, Ren X, Wang Y, Boivin GP et al. Cardiac-specific blockade of NF-kappaB in cardiac pathophysiology: differences between acute and chronic stimuli in vivo. Am J Physiol Heart Circ Physiol 2005;289:H466-H476.
20. Onai Y, Suzuki J, Kakuta T, Maejima Y, Haraguchi G, Fukasawa H et al. Inhibition of IkappaB phosphorylation in cardiomyocytes attenuates myocardial ischemia/reperfusion injury. Cardiovasc Res 2004;63:51-59.
21. Frantz S, Tillmanns J, Kuhlencordt PJ, Schmidt I, Adamek A, Dienesch C et al. Tissue-specific effects of the nuclear factor {kappa}B subunit p50 on myocardial ischemia-reperfusion injury. Am J Pathol 2007;171:507-512.
22. Tillmanns J, Carlsen H, Blomhoff R, Valen G, Calvillo L, Ertl G et al. Caught in the act: in vivo molecular imaging of the transcription factor NF-kappaB after myocardial infarction. Biochem Biophys Res Commun 2006;342:773-774.
23. Frantz S, Fraccarollo D, Wagner H, Behr TM, Jung P, Angermann CE et al. Sustained activation of nuclear factor kappa B and activator protein 1 in chronic heart failure. Cardiovasc Res 2003;57:749-756.
24. Frantz S, Hu K, Bayer B, Gerondakis S, Strotmann J, Adamek A et al. Absence of NF-kappaB subunit p50 improves heart failure after myocardial infarction. FASEB J 2006;20:1918-1920.
25. Weisman HF, Bartow T, Leppo MK, Marsh HC Jr, Carson GR, Concino MF et al. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990;249:146-151.
26. Carroll MC, Prodeus AP. Linkages of innate and adaptive immunity. Curr Opin Immunol 1998;10:36-40.
27. Tanhehco EJ, Yasojima K, McGeer PL, Washington RA, Kilgore KS, Homeister JW et al. Preconditioning reduces tissue complement gene expression in the rabbit isolated heart. Am J Physiol 1999;277:H2373-H2380.
28. Weiser MR, Williams JP, Moore FD Jr, Kobzik L, Ma M, Hechtman HB et al. Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement. J Exp Med 1996;183:2343-2348.
29. Williams JP, Pechet TT, Weiser MR, Reid R, Kobzik L, Moore FD Jr et al. Intestinal reperfusion injury is mediated by IgM and complement. J Appl Physiol 1999;86:938-942.
30. Zhang M, Alicot EM, Chiu I, Li J, Verna N, Vorup-Jensen T et al. Identification of the target self-antigens in reperfusion injury. J Exp Med 2006;203:141-152.
31. Zhang M, Michael LH, Grosjean SA, Kelly RA, Carroll MC, Entman ML. The role of natural IgM in myocardial ischemia-reperfusion injury. J Mol Cell Cardiol 2006;41:62-67.
32. Dreyer WJ, Michael LH, Nguyen T, Smith CW, Anderson DC, Entman ML et al. Kinetics of C5a release in cardiac lymph of dogs experiencing coronary artery ischemia-reperfusion injury. Circ Res 1992;71:1518-1524.
33. Josephson RA, Silverman HS, Lakatta EG, Stern MD, Zweier JL. Study of the mechanisms of hydrogen peroxide and hydroxyl free radical-induced cellular injury and calcium overload in cardiac myocytes. J Biol Chem 1991;266:2354-2361.
34. Grieve DJ, Shah AM. Oxidative stress in heart failure. More than just damage. Eur Heart J 2003;24:2161-2163.
35. Byrne JA, Grieve DJ, Cave AC, Shah AM. Oxidative stress and heart failure. Arch Mal Coeur Vaiss 2003;96:214-221.
36. Heymes C, Bendall JK, Ratajczak P, Cave AC, Samuel JL, Hasenfuss G et al. Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol 2003;41:2164-2171.
37. Frantz S, Brandes RP, Hu K, Rammelt K, Wolf J, Scheuermann H et al. Left ventricular remodeling after myocardial infarction in mice with targeted deletion of the NADPH oxidase subunit gp91(PHOX). Basic Res Cardiol 2006;101:127-132.
38. Hill MF, Singal PK. Antioxidant and oxidative stress changes during heart failure subsequent to myocardial infarction in rats. Am J Pathol 1996;148:291-300.
39. Murdoch CE, Zhang M, Cave AC, Shah AM. NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure. Cardiovasc Res 2006;71:208-215.
40. Shiomi T, Tsutsui H, Matsusaka H, Murakami K, Hayashidani S, Ikeuchi M et al. Overexpression of glutathione peroxidase prevents left ventricular remodeling and failure after myocardial infarction in mice. Circulation 2004;109:544-549.
41. Opal SM, Esmon CT. Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Crit Care 2003;7:23-38.
42. Nahrendorf M, Hu K, Frantz S, Jaffer FA, Tung CH, Hiller KH et al. Factor XIII deficiency causes cardiac rupture, impairs wound healing, and aggravates cardiac remodeling in mice with myocardial infarction. Circulation 2006;113:1196-1202.
43. Nahrendorf M, Aikawa E, Figueiredo JL, Stangenberg L, van den Borne SW, Blankesteijn WM et al. Transglutaminase activity in acute infarcts predicts healing outcome and left ventricular remodelling: implications for FXIII therapy and antithrombin use in myocardial infarction. Eur Heart J 2008;29:445-454.
44. Gemmati D, Federici F, Campo G, Tognazzo S, Serino ML, De Mattei M et al. Factor XIIIA-V34L and factor XIIIB-H95R gene variants: effects on survival in myocardial infarction patients. Mol Med 2007;13:112- 120.
45. Fraccarollo D, Galuppo P, Schraut S, Kneitz S, van Rooijen N, Ertl G et al. Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response. Hypertension 2008;51:905-914.
46. Hasdai D, Scheinowitz M, Leibovitz E, Sclarovsky S, Eldar M, Barak V. Increased serum concentrations of interleukin-1 beta in patients with coronary artery disease. Heart 1996;76:24-28.
47. Guillen I, Blanes M, Gomez-Lechon MJ, Castell JV. Cytokine signaling during myocardial infarction: sequential appearance of IL-1 beta and IL-6. Am J Physiol 1995;269:R229-R235.
48. Han R, Ray P, Baughman K, Feldman A. Detection of interleukin 1 and interleukin-1-receptor mRNA in human heart by polymerase chain reaction. Biochem Biophys Res Commun 1991;181:520-523.
49. Francis SE, Holden H, Holt CM, Duff GW. Interleukin-1 in myocardium and coronary arteries of patients with dilated cardiomyopathy. J Mol Cell Cardiol 1998;30:215-223.
50. Testa M, Yeh M, Lee P, Fanelli R, Loperfido F, Berman JW et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 1996;28:964-971.
51. Herskowitz A, Choi S, Ansari AA, Wesselingh S. Cytokine mRNA expression in postischemic/reperfused myocardium. Am J Pathol 1995;146:419- 428.
52. Brown JM, Anderson BO, Repine JE, Shanley PF, White CW, Grosso MA et al. Neutrophils contribute to TNF induced myocardial tolerance to ischaemia. J Mol Cell Cardiol 1992;24:485-495.
53. Brown JM, White CW, Terada LS, Grosso MA, Shanley PF, Mulvin DW et al. Interleukin 1 pretreatment decreases ischemia/reperfusion injury. Proc Natl Acad Sci USA 1990;87:5026-5030.
54. Nogae C, Makino N, Hata T, Nogae I, Takahashi S, Suzuki K et al. Interleukin 1 alpha-induced expression of manganous superoxide dismutase reduces myocardial reperfusion injury in the rat. J Mol Cell Cardiol 1995;27:2091-2099.
55. Frantz S, Ducharme A, Sawyer D, Rohde LE, Kobzik L, Fukazawa R et al. Targeted deletion of caspase-1 reduces early mortality and left ventricular dilatation following myocardial infarction. J Mol Cell Cardiol 2003;35:685-694.
56. Merkle S, Frantz S, Schon MP, Bauersachs J, Buitrago M, Frost RJ et al. A role for caspase-1 in heart failure. Circ Res 2007;100:645-653.
57. Bujak M, Dobaczewski M, Chatila K, Mendoza LH, Li N, Reddy A et al. Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling. Am J Pathol 2008;173:57-67.
58. Kubota T, McTiernan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 1997;81:627-635.
59. Bryant D, Becker L, Richardson J, Shelton J, Franco F, Peshock R et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation 1998;97:1375-1381.
60. Bozkurt B, Kribbs SB, Clubb FJ Jr, Michael LH, Didenko VV, Hornsby PJ et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998;97:1382-1391.
61. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996;27:1201-1206.
62. Dunlay SM, Weston SA, Redfield MM, Killian JM, Roger VL. Tumor necrosis factor-alpha and mortality in heart failure: a community study. Circulation 2008;118:625-631.
63. Kurrelmeyer KM, Michael LH, Baumgarten G, Taffet GE, Peschon JJ, Sivasubramanian N et al. Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. Proc Natl Acad Sci USA 2000;97:5456- 5461.
64. Gillitzer R, Goebeler M. Chemokines in cutaneous wound healing. J Leukoc Biol 2001;69:513-521.
65. Frangogiannis NG. The mechanistic basis of infarct healing. Antioxid Redox Signal 2006;8:1907-1939.
66. Boyle EM Jr, Kovacich JC, Hebert CA, Canty TG Jr, Chi E, Morgan EN et al. Inhibition of interleukin-8 blocks myocardial ischemia-reperfusion injury. J Thorac Cardiovasc Surg 1998;116:114-121.
67. Jones SP, Trocha SD, Strange MB, Granger DN, Kevil CG, Bullard DC et al. Leukocyte and endothelial cell adhesion molecules in a chronic murine model of myocardial reperfusion injury. Am J Physiol 2000;279: H2196-H2201.
68. Ma XL, Weyrich AS, Lefer DJ, Buerke M, Albertine KH, Kishimoto TK et al. Monoclonal antibody to L-selectin attenuates neutrophil accumulation and protects ischemic reperfused cat myocardium. Circulation 1993;88:649-658.
69. Litt MR, Jeremy RW, Weisman HF, Winkelstein JA, Becker LC. Neutrophil depletion limited to reperfusion reduces myocardial infarct size after 90 min of ischemia. Evidence for neutrophil-mediated reperfusion injury. Circulation 1989;80:1816-1827.
70. Metzler B, Mair J, Lercher A, Schaber C, Hintringer F, Pachinger O et al. Mouse model of myocardial remodelling after ischemia: role of intercellular adhesion molecule-1. Cardiovasc Res 2001;49:399-407.
71. Simpson DM, Ross R. The neutrophilic leukocyte in wound repair: a study with antineutrophil serum. J Clin Invest 1972;51:2009-2023.
72. Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo JL et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med 2007;204:3037-3047.
73. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994;331:1286-1292.
74. Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res 2004;63:423-432.
75. Deten A, Holzl A, Leicht M, Barth W, Zimmer HG. Changes in extracellular matrix and in transforming growth factor beta isoforms after coronary artery ligation in rats. J Mol Cell Cardiol 2001;33:1191-1207.
76. Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K et al. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 2002;106:130-135.
77. Frantz S, Hu K, Adamek A, Wolf J, Sallam A, Maier SK et al. Transforming growth factor beta inhibition increases mortality and left ventricular dilatation after myocardial infarction. Basic Res Cardiol 2008;103:485-492.
78. Vakeva AP, Agah A, Rollins SA, Matis LA, Li L, Stahl GL. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 1998;97:2259-2267.
79. Mahaffey KW, Granger CB, Nicolau JC, Ruzyllo W, Weaver WD, Theroux P et al. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation 2003;108:1176-1183.
80. Granger CB, Mahaffey KW, Weaver WD, Theroux P, Hochman JS, Filloon TG et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 2003;108:1184-1190.
81. Faxon DP, Gibbons RJ, Chronos NA, Gurbel PA, Sheehan F. The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study. J Am Coll Cardiol 2002;40:1199-1204.
82. Giugliano GR, Giugliano RP, Gibson CM, Kuntz RE. Meta-analysis of corticosteroid treatment in acute myocardial infarction. Am J Cardiol 2003;91:1055-1059.
83. Greenberg B, Zannad F, Pitt B. Role of aldosterone blockade for treatment of heart failure and post-acute myocardial infarction. Am J Cardiol 2006;97:34F-40F.
84. Ashcroft GS, Horan MA, Ferguson MW. Aging is associated with reduced deposition of specific extracellular matrix components, an upregulation of angiogenesis, and an altered inflammatory response in a murine incisional wound healing model. J Invest Dermatol 1997;108:430-437.
85. von Haehling S, Genth-Zotz S, Sharma R, Bolger AP, Doehner W, Barnes PJ et al. The relationship between age and production of tumour necrosis factor-alpha in healthy volunteers and patients with chronic heart failure. Int J Cardiol 2003;90:197-204.
86. Ferrari R. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) study. Arch Intern Med 2006;166:659-666.